Peramivir Patent Expiration

Peramivir is Used for treating acute uncomplicated influenza in patients 6 months and older. It was first introduced by Biocryst Pharmaceuticals Inc in its drug Rapivab on Dec 19, 2014.


Peramivir Patents

Given below is the list of patents protecting Peramivir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rapivab US8778997 Antiviral treatments May 07, 2027 Biocryst
Rapivab US10391075 Antiviral treatments Feb 12, 2027 Biocryst
Rapivab US6562861 Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors Dec 16, 2023

(Expired)

Biocryst
Rapivab US6503745 Cyclopentane and cyclopentene compounds and use for detecting influenza virus Nov 05, 2019

(Expired)

Biocryst



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Peramivir's patents.

Given below is the list recent legal activities going on the following patents of Peramivir.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 15 Feb, 2023 US10391075
Payment of Maintenance Fee, 8th Year, Large Entity 29 Dec, 2021 US8778997
Recordation of Patent Grant Mailed 27 Aug, 2019 US10391075
Patent Issue Date Used in PTA Calculation 27 Aug, 2019 US10391075
Email Notification 08 Aug, 2019 US10391075
Issue Notification Mailed 07 Aug, 2019 US10391075
Dispatch to FDC 29 Jul, 2019 US10391075
Application Is Considered Ready for Issue 19 Jul, 2019 US10391075
Issue Fee Payment Verified 12 Jul, 2019 US10391075
Issue Fee Payment Received 12 Jul, 2019 US10391075


Peramivir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List